Simplifying Global Compliance
EMEA: Risk Management Plans Should Address Vaccine Concerns
Clinical Trials Advisor
Vaccine safety concerns that emerge before marketing should be investigated during preauthorization and addressed in the manufacturer’s risk management plan (RMP), according to a European Medicines Agency (EMEA) draft guideline.
To View This Article:
Subscribe To Clinical Trials Advisor
Buy This Article Now
Copyright ©2019. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing